Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04710797
Other study ID # 2020-FXY-405
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 31, 2021
Est. completion date December 31, 2028

Study information

Verified date January 2021
Source Sun Yat-sen University
Contact Jihong Liu, Ph.D.
Phone 86-20-87343102
Email liujih@mail.sysu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the impact of comprehensive staging surgery with no lymphadenectomy on survival and quality of life in patients with early-stage ovarian cancer.


Description:

OBJECTIVES: Compare the efficacy and safety in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IA -IIA epithelial ovarian cancer, undergo completion staging surgery including systematic pelvic and para-aortic lymphadenectomy versus comprehensive staging surgery without lymphadenectomy. OUTLINE: This is a randomized phase III multicenter study. Patients will receive comprehensive staging surgery without Lymphadenectomy or completion staging surgery including systematic pelvic and para-aortic lymphadenectomy, and the adjuvant chemotherapy will accord to National Comprehensive Cancer Network (NCCN) guidelines. Patients are followed up every 3 months within the first 2 years, and then every 6 months. PROJECTED ACCRUAL: A total of 656 patients will be recruited for this study within 5 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 656
Est. completion date December 31, 2028
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Women aged 18 years to 70 years. 2. Primary diagnosis of epithelial ovarian cancer FIGO stage IA-IIA ( recevive no prior treatment or receive incomplete initial surgery),with indications of adjuvant chemotherapy:?High-grade serous carcinoma; ?Grade 3 endometrioid carcinoma; ?Clear cell carcinoma; ?Grade 2 endometrioid carcinoma with capsule ruptured or pelvic tissues extension ?Low-grade serous carcinoma?Grade 1 endometrioid carcinoma and Mucinous carcinoma of the ovary with pelvic tissues extension. 3. Patients who have given their signed and written informed consent. 4. Good performance status (ECOG 0/1). Exclusion Criteria: 1. Non epithelial ovarian malignancies and borderline tumors. 2. Suspicious lymph nodes at preoperative radiological evaluation. 3. Intraoperative clinically suspicious lymph nodes (bulky nodes). 4. Secondary invasive neoplasms in the last 5 years (except synchronal endometrial carcinoma FIGO IA G1/2, non melanoma skin cancer, breast cancer T1 N0 M0 G1/2) or with any signs of relapse or activity. 5. Prior chemotherapy for ovarian cancer or abdominal/pelvic radiotherapy. 6. Diseases of the lymph system (including lymph edema of unknown origin). 7. Prior retroperitoneal lymph node dissection (systematic or sampling). 8. Any other concurrent medical conditions contraindicating surgery. 9. Pregnancy. 10. Any reasons interfering with giving of informed consent , abiding by protocol, or regular follow-up.

Study Design


Intervention

Procedure:
Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy
open or minimally invasive surgical approach cytologic examinations All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied BSO and hysterectomy For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered Omentectomy Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve
Comprehensive staging surgery with no Lymphadenectomy
open or minimally invasive surgical approach cytologic examinations All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied BSO and hysterectomy For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered Omentectomy In open approach surgery, exploring the pelvic and Para-aortic lymph node with hand. In minimally invasive surgery, the peritoneal above the pelvic and Para-aortic lymph node area should be open and visualized.Biopsy and frozen section of the suspicious lymph nodes

Locations

Country Name City State
China Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary PFS(Progression-free survival) From date of randomization until the date of first documented progression or date of death from any cause, whichever came first From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Secondary OS(Overall Survival) From date of randomization until the date of death from any cause or date of last follow up, whichever came first From date of randomization until the date of death from any cause or date of last follow up, up to 100 mons
Secondary Recurrence rate of lymph node The recurrence rate in the retroperitoneal lymph nodes after primary surgery 3 years
Secondary QoL(Quality of life) Quality of life before surgery, and at 6 months and 1 year after surgery in both groups will be evaluated using European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Baseline, 6 months and 1 year after surgery
Secondary Postoperative complications The difference of the rate of Postoperative complications between two groups 3 years
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2